Drug intelligence / Profile preview

AKG-240

Development stage: Preclinical
Lead developer: Akagera Medicines
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

AKG-240 is a preclinical-stage mRNA-based prophylactic vaccine candidate being developed by Akagera Medicines for the prevention of influenza. Designed as a multivalent vaccine, AKG-240 aims to provide broad protection against multiple circulating strains of the influenza virus. The vaccine utilizes mRNA technology to encode viral antigens, which, upon delivery (typically via lipid nanoparticles), are expressed by the recipient's cells to elicit a robust and specific immune response. This approach is intended to offer a more flexible and rapidly scalable alternative to traditional egg-based or cell-based influenza vaccine manufacturing.

Other names: Akagera mRNA-LNP influenza vaccineligand-directed mRNA-LNP influenza vaccine

Beyond the preview

Go deeper on AKG-240.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AKG-240.

Explore the full profile